Acadia Pharmaceuticals (ACAD) Non-Current Deffered Revenue (2010 - 2012)

Acadia Pharmaceuticals' Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $2.4 million for Q2 2012.

• In Q2 2012, Non-Current Deffered Revenue fell 3.02% year-over-year to $2.4 million; the TTM figure through Jun 2012 stood at $2.4 million (down 3.02% YoY), while the FY2011 annual figure was $2.6 million, down 1.37% from the prior year.
• Non-Current Deffered Revenue was $2.4 million for Q2 2012 at Acadia Pharmaceuticals, down from $2.5 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $2.6 million in Q4 2010 to a low of $2.4 million in Q2 2012.
• Historically, Non-Current Deffered Revenue has averaged $2.5 million across 3 years, with a median of $2.5 million in 2011.
• The sharpest annual moves came in 2011 and 2012: Non-Current Deffered Revenue declined 1.37% in 2011, then declined 3.02% in 2012.
• A 3-year view of Non-Current Deffered Revenue shows it stood at $2.6 million in 2010, then dropped by 1.37% to $2.6 million in 2011, then declined by 7.0% to $2.4 million in 2012.
• The last three Non-Current Deffered Revenue figures came in at $2.4 million (Q2 2012), $2.5 million (Q1 2012), and $2.6 million (Q4 2011), per Business Quant data.